I-BET151 (GSK1210151A): Selective BET Inhibitor for Cancer Biology & Epigenetic Research

Executive Summary: I-BET151 (GSK1210151A) is a selective inhibitor targeting BET family bromodomains (BRD2, BRD3, BRD4) with nanomolar to sub-micromolar IC₅₀ values, disrupting oncogenic transcriptional programs in various cancer models (APExBIO). BET inhibition by I-BET151 reduces tumor volume and promotes apoptosis and cell cycle arrest in vivo and in vitro (Kang et al., 2025). Super-enhancer regulation and transcriptional modulation are central mechanisms of action, with broad utility in MLL-fusion leukemia and glioblastoma research. I-BET151's formulation parameters (solubility: ≥41.5 mg/mL in DMSO, storage: -20°C) enable reproducible workflows. Recent studies emphasize the role of BET inhibitors in modulating emerging cell death pathways, such as disulfidptosis, and in dissecting super-enhancer-driven oncogenic circuits (BET Bromodomain Inhibition in the Era of Super-Enhancer-Driven Cancer).

Biological Rationale

BET (bromodomain and extraterminal) proteins, including BRD2, BRD3, and BRD4, are epigenetic readers that recognize acetylated lysine residues on histone tails and regulate chromatin structure and gene expression. Aberrant BET activity is associated with oncogenic transcriptional programs, especially in cancers driven by super-enhancer (SE) landscapes and fusion oncogenes such as MLL-fusions (Kang et al., 2025). Recent findings highlight the importance of SE/FOXA1/SLC7A11 regulatory axes in tumor progression and novel cell death mechanisms (disulfidptosis) in prostate cancer. Targeting BET proteins allows for the disruption of pathogenic gene expression patterns, cell cycle progression, and cancer cell survival (Advanced Insights in BET Protein Signaling—this article details updated evidence on super-enhancer targeting and cell death pathways beyond prior reviews).

Mechanism of Action of I-BET151 (GSK1210151A)

I-BET151 (SKU B1500) is a potent, selective inhibitor of the BET bromodomain family, binding competitively to the acetyl-lysine recognition pocket of BRD2 (IC₅₀ = 0.5 μM), BRD3 (IC₅₀ = 0.25 μM), and BRD4 (IC₅₀ = 0.79 μM) (APExBIO). By blocking the interaction of BET proteins with chromatin, I-BET151 impedes the assembly of transcriptional complexes at super-enhancers and oncogenic loci. This results in downregulation of key survival and proliferation genes (such as MYC and BCL2), induction of G1 phase arrest, and initiation of apoptosis in sensitive cell types. In glioblastoma U87MG cells, I-BET151 induces G1 arrest and apoptosis in a dose- and time-dependent manner. In vivo, BET inhibition reduces tumor growth and prolongs survival in xenograft and leukemia models. The selectivity profile of I-BET151 minimizes off-target effects common to pan-bromodomain inhibitors, supporting its use in precise mechanistic studies (I-BET151: Selective BET Inhibitor for Cancer Biology & Epigenetic Research—this article extends previous methodology by integrating super-enhancer context and disulfidptosis evidence).

Evidence & Benchmarks

• I-BET151 inhibits BRD2 (IC₅₀ = 0.5 μM), BRD3 (IC₅₀ = 0.25 μM), and BRD4 (IC₅₀ = 0.79 μM) in biochemical assays (APExBIO).
• In mouse xenograft models of myeloma and glioblastoma, I-BET151 significantly reduces tumor volume and increases survival rates (Kang et al., 2025, DOI).
• I-BET151 induces G1 cell cycle arrest and apoptosis in glioblastoma U87MG cells in a dose- and time-responsive manner (Kang et al., 2025, DOI).
• Bromodomain inhibition by I-BET151 blocks super-enhancer-driven expression of SLC7A11 and FOXA1 regulatory axes in prostate cancer, affecting disulfidptosis susceptibility (Kang et al., 2025, DOI).
• Solubility benchmarks: ≥41.5 mg/mL in DMSO, ≥19.5 mg/mL in ethanol; insoluble in water. Storage recommended at -20°C. Warming to 37°C or ultrasonic bath enhances dissolution (APExBIO).

Applications, Limits & Misconceptions

I-BET151 is primarily used in research on cancer biology, epigenetic regulation, and transcriptional modulation. Its efficacy is demonstrated in MLL-fusion leukemia, glioblastoma, and prostate cancer models characterized by super-enhancer-driven gene expression. I-BET151 supports apoptosis and cell cycle arrest assays, serving as a control for BET protein pathway inhibition (I-BET151: Selective BET Inhibitor for Cancer Biology & Epigenetic Research—this article clarifies real-world protocol boundaries and troubleshooting in contrast to the current mechanistic review). Recent studies also implicate BET inhibition in the modulation of disulfidptosis, a novel cell death pathway linked to SLC7A11 and FOXA1 super-enhancer axes.

Common Pitfalls or Misconceptions

• I-BET151 is not effective in cell lines lacking BET protein dependency or super-enhancer-driven transcriptional programs.
• It is not suitable for clinical or therapeutic use; research-only reagent status applies.
• Water is not a suitable solvent; use DMSO or ethanol for solution preparation.
• Prolonged storage of solutions at room temperature leads to degradation; follow short-term use and -20°C storage guidelines.
• BET inhibition may not trigger apoptosis in all tumor types; effectiveness is context- and model-dependent.

Workflow Integration & Parameters

I-BET151 (GSK1210151A, B1500) is supplied as a crystalline solid (MW 415.44, C₂₃H₂₁N₅O₃) by APExBIO. Prepare stock solutions at ≥41.5 mg/mL in DMSO or ≥19.5 mg/mL in ethanol. Solutions should be freshly prepared, with warming to 37°C or ultrasonic bath recommended for rapid dissolution. Store lyophilized powder or solutions at -20°C. For apoptosis or cell cycle arrest assays, dose ranges from 0.1 μM to 10 μM are typical, with time courses of 24–72 hours depending on cell type and endpoint. For in vivo models, dosing should be guided by published protocols to ensure pharmacodynamic coverage and minimal off-target toxicity (Reliable BET Bromodomain Inhibitor for Workflow Integration—this article expands on scenario-driven best practices and experimental troubleshooting for the modern user).

Conclusion & Outlook

I-BET151 (GSK1210151A) remains a gold-standard BET bromodomain inhibitor for dissecting epigenetic regulation and transcriptional modulation in cancer biology. Its high selectivity, robust solubility, and well-characterized mechanistic profile enable reproducible assay outcomes across diverse models, from MLL-fusion leukemia to emerging super-enhancer-driven tumor types. The integration of I-BET151 into workflows investigating disulfidptosis and novel cell death modalities underscores its translational relevance. Ongoing research on SE/FOXA1/SLC7A11 axes and BET protein signaling will further illuminate therapeutic strategies and expand the applications of selective BET inhibition in precision oncology.